ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Recruiting · NCT06816992 · Registry updated 2026-04-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | non-small cell lung carcinoma | Recruiting | Phase 1 | 2026-04-24 | NCT06816992 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Research & Development, LLC | 188 |
| ORIC Pharmaceuticals | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| NYU Langone Health | New York | United States | 403 |
| Peter Maccallum Cancer Centre | Melbourne | Australia | 5 |
| The Princess Margaret Hospital | Toronto | Canada | 1 |
| Virginia Cancer Specialists | Fairfax | United States | 109 |